The Pancreatic Cancer Action Network Increases Biomarker-Driven Clinical Trial Matching Capabilities by nearly 300% with GenomOncology
June 9, 2021
CLEVELAND, June 9, 2021 -- GenomOncology announced today that the Pancreatic Cancer Action Network (PanCAN) has chosen to upgrade to GenomOncology’s Precision Decision to further enhance the free clinical trial matching services it offers to pancreatic cancer patients.
Through its comprehensive Patient Services program, PanCAN is committed to matching patients to the best treatment opportunities to create a world in which all patients with pancreatic cancer will thrive. PanCAN strongly recommends pancreatic cancer patients consider clinical trials at diagnosis as well as during every treatment decision, and according to research from the organization, patients who receive treatment based on their tumor's biological characteristics have better outcomes.
In 2020, PanCAN implemented GenomOncology’s Clinical Trial Matching solution in order to streamline the organization’s biomarker-driven clinical trial matching process. PanCAN chose GenomOncology due to their overall industry knowledge and expertise, as well as the breadth of clinical trial curation available within the solution. Since the implementation of GenomOncology’s Clinical Trial Matching Solution, PanCAN has increased the number of biomarker-driven searches by 300% and has reduced the time spent on biomarker clinical trial searches by 50%. Due to this success, PanCAN has decided to upgrade to GenomOncology's Precision Decision solution.
With Precision Decision, PanCAN will have access to enhanced clinical trial and therapy matching due to the combination of automation and quality assurance, which results in the aggregation of available variant, disease, and patient data. Precision Decision will also enable the PanCAN team to advance their treatment searching capabilities through the addition of the patient's prior intervention history, such as chemotherapy, surgery, radiation, targeted therapy administration, or if they have participated in other clinical trials.
“It’s important for PanCAN’s Patient Services team to be able to provide fast, reliable and personalized information to support patients in their treatment journey,” said Lynn Matrisian, PanCAN's Chief Science Officer. “By implementing GenomOncology’s Clinical Trial Matching Solution, we have been able to serve our patients faster and more accurately in finding biomarker-driven clinical trials specifically relevant to them.”
“Precision Decision will further advance the patient treatment matching capabilities of the PanCAN team. The ability to dive deeper into a patient population, including their prior interventions, will narrow down the best treatment option for a patient significantly, and will ultimately help improve potential outcomes,” said GenomOncology’s Joe McCrone, Vice President of Client Services.
About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive.
GenomOncology provides the healthcare community with data-driven insights to improve cancer care. GenomOncology strengthens your precision oncology program by transforming valuable, but unusable data, into actionable oncology treatment options and strategic insights. GenomOncology’s Precision Oncology Platform (POP) powers its comprehensive set of end-to-end software solutions that enhance decision support. POP combines both proprietary content and public and licensed data sets with your internal patient data to provide you the information necessary to improve patient outcomes. Learn more at www.genomoncology.com.
Senior Manager, Public Relations
Pancreatic Cancer Action Network
Direct: +1-949-244-2561 | E-mail:
Director of Marketing
Direct: (440) 617-6087| E-mail: